SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Basit Öğe Kaydı
dc.contributor.authorEfe, Cumali
dc.contributor.authorTascilar, Koray
dc.contributor.authorGerussi, Alessio
dc.contributor.authorBolis, Francesca
dc.contributor.authorLammert, Craig
dc.contributor.authorEbik, Berat
dc.contributor.authorStattermayer, Albert Friedrich
dc.date.accessioned2024-02-23T14:12:33Z
dc.date.available2024-02-23T14:12:33Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractBackground: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARSCoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.en_US
dc.description.sponsorshipTurkish Association for the Study of Liver (TASL); Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)en_US
dc.description.sponsorshipTurkish Association for the Study of Liver (TASL) organized and supported data collection of Turkish patients.; A. Gerussi, and P. Invernizzi acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic).en_US
dc.identifier.doi10.1016/j.jaut.2022.102906
dc.identifier.issn0896-8411
dc.identifier.issn1095-9157
dc.identifier.pmid36088883en_US
dc.identifier.scopus2-s2.0-85137350048en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.jaut.2022.102906
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12106
dc.identifier.volume132en_US
dc.identifier.wosWOS:000911713800005en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Ltd- Elsevier Science Ltden_US
dc.relation.ispartofJournal Of Autoimmunityen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLiver Failureen_US
dc.subjectBreakthrough Infectionen_US
dc.subjectImmunosuppressionen_US
dc.subjectVaccineen_US
dc.subjectAutoimmunityen_US
dc.titleSARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu